Alaunos Therapeutics General Counsel Melinda Lackey Departs for Valion Bio
Alaunos Therapeutics veteran Melinda Lackey, Senior Vice President of Legal & Administration, departs after overseeing IP strategy and compliance for clinical-stage oncology cell therapy programs. She brought nearly two decades of biopharmaceutical development, intellectual property and Nasdaq governance experience to the company.
1. Senior Legal Leadership Departure
Melinda Lackey has vacated her role as Senior Vice President of Legal & Administration at Alaunos Therapeutics, where she managed all legal, compliance and IP functions for the Nasdaq-listed oncology cell therapy developer. Her responsibilities included negotiating clinical trial agreements, overseeing regulatory filings and guiding capital markets disclosures.
2. Governance and Operational Implications
Her exit creates a leadership gap in intellectual property strategy and public company governance on the eve of key clinical milestones. The company must appoint a successor to maintain compliance with FDA regulations, sustain IP portfolio growth and ensure uninterrupted support for ongoing trials.